June 1, 2017
News & Publications
Press Releases
May 1, 2017
H3 Biomedicine Appoints Lihua Yu, Ph.D., to Chief Data Sciences Officer
Read More »
April 20, 2017
H3 Biomedicine Extends Collaboration with Foundation Medicine to Develop Precision Therapies for Cancer
Read More »
April 4, 2017
H3 Biomedicine Presents New Data from its RNA Splicing Platform at AACR
Includes the Characterization of Splicing Modulator Mechanism of Action and Demonstration of Pre-clinical Efficacy of H3B-8800 in Spliceosome Mutant Cancers,… Read More »
April 2, 2017
H3 Biomedicine to Present Data on Emerging Pipeline Compounds
Data Updates on FGFR4 Inhibitor for Hepatocellular Carcinoma (HCC) and Novel Selective Estrogen Receptor Covalent Receptor (SERCA) Identified for Breast… Read More »
March 9, 2017
H3 Biomedicine to Present New Data from Recent Research Advancements at 2017 American Association of Cancer Research Annual Meeting
Read More »In the Media
Boston Business Journal
H3 Biomedicine to Begin Trials of First-Ever Gene-Splicing Cancer Drug
Kendall Square-based cancer biotech H3 Biomedicine, created five years ago by Japanese drug firm Eisai, will bring its first drug… Read More »
PharmaVOICE
H3 Biomedicine’s Dr. Lihua Yu Honored in PharmaVOICE 100
In her position as VP, data science and information technology, at H3 Biomedicine, Lihua Yu, Ph.D., is driving the expanded… Read More »
Boston Business Journal
Foundation Medicine, H3 Biomedicine Partner to Develop Cancer Drugs
A partnership announced today between two Cambridge companies, Foundation Medicine (Nasdaq: FMI) and H3 Biomedicine, is further evidence of the… Read More »
FasterCures
Fixes in Financing
High-risk, long-term investments are needed to turn medical innovations into lifesaving therapies. At FasterCures, we examine and highlight innovative funding mechanisms… Read More »Scientific Publications
Cancer Cell
Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia
Mutations in SF3B1, which encodes a spliceosome component, are associated with poor outcome in chronic lymphocytic leukemia (CLL), but how… Read More »
Leukemia
Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts
Heterozygous somatic mutations affecting the spliceosome gene SF3B1 drive age-related clonal hematopoiesis, myelodysplastic syndromes (MDS) and other neoplasms. Read More »
Cancer Cell
Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation
More than 80% of patients with the refractory anemia with ring sideroblasts subtype of myelodysplastic syndrome (MDS) have mutations in… Read More »
Nature Medicine
Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins
Mutations in genes encoding splicing factors (which we refer to as spliceosomal genes) are commonly found in patients with myelodysplastic… Read More »Media Inquiries
For all media interested in speaking to members of H3 Biomedicine’s executive/scientific team, or receiving further information about the company or pipeline, please forward your request to Paul Kidwell.
